Nama's AI scorecard currently rates Stevanato Group Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is STVN's P/E ratio?

Stevanato Group trades at a trailing price-to-earnings ratio of 20.0.

When does STVN report earnings?

Stevanato Group's next scheduled report is on Mar 3, 2027. Analysts expect EPS of $0.23.

What is the STVN price target?

The median analyst price target from 12 analysts is $21.75, with a range of $16.00 – $32.00.

Is STVN Shariah compliant?

Nama's AAOIFI-style screen reads Stevanato Group as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does STVN pay a dividend?

Yes — Stevanato Group's dividend yield is 0.4%.

Nama Insights

Stevanato Group (STVN)

Healthcare · Medical Instruments Supplies · NYSE

Stevanato Group (STVN) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $3.71B, a trailing price-to-earnings ratio of 20.0 and a free-cash-flow yield of 0.4%. Over the most recent reported fiscal year, revenue grew 7.5%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 6.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -20.4% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-62.6%

How far the last close sits under the highest price of the past five years.

Market cap	$3.71B
Trailing P/E	20.0
Price / book	2.1
Price / sales	2.7
FCF yield	0.4%
Dividend yield	0.4%
Gross margin	29.2%
Operating margin	17.4%
Net margin	11.0%
Revenue growth (YoY)	+7.5%
Revenue growth (3-yr annual)	+6.4%
EPS growth (YoY)	+17.3%
FCF/share growth (YoY)	—
Beta	0.8
Exchange	NYSE
Sector	Healthcare
Industry	Medical Instruments Supplies

STVN earnings

Next report: Mar 3, 2027 (Q4 2026, EPS estimate $0.23). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$0.18	$0.18	+0.0%	$363.87M
Q2 2026	Aug 4, 2026	$0.16	$0.15	+6.7%	$337.02M
Q1 2026	May 7, 2026	$0.13	$0.12	+8.3%	$305.29M
Q4 2025	Mar 4, 2026	$0.21	$0.20	+5.0%	$386.66M

STVN analyst price target

Median target $21.75 from 12 analysts, ranging $16.00 – $32.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live STVN data on Nama Insights →

STVN FAQ

Is STVN a buy?: Nama's AI scorecard currently rates Stevanato Group Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is STVN's P/E ratio?: Stevanato Group trades at a trailing price-to-earnings ratio of 20.0.
When does STVN report earnings?: Stevanato Group's next scheduled report is on Mar 3, 2027. Analysts expect EPS of $0.23.
What is the STVN price target?: The median analyst price target from 12 analysts is $21.75, with a range of $16.00 – $32.00.
Is STVN Shariah compliant?: Nama's AAOIFI-style screen reads Stevanato Group as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does STVN pay a dividend?: Yes — Stevanato Group's dividend yield is 0.4%.